MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tew, K. D.
Right arrow Articles by Hartley-Asp, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tew, K. D.
Right arrow Articles by Hartley-Asp, B.

Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets

KD Tew, LC Erickson, G White, AL Wang, PS Schein and B Hartley-Asp

Estramustine is cytotoxic in HeLa and Walker 256 carcinoma cells (with or without acquired resistance to nitrogen mustards) at concentrations equivalent to other alkylating agents. Even at lethal estramustine levels, no damage to DNA occurs. Instead, a disproportionately high amount of intact estramustine binds hydrophobically to the structural proteins of the nucleus, the nuclear matrix. In HeLa cells, estradiol receptors are absent, and estradiol per se is not toxic. Thus, estramustine has a mechanism of action distinct from that of steroids and alkylating agents and may induce cytotoxicity through interactions with the proteins of the nuclear matrix.

Volume 24, Issue 2, pp. 324-328, 09/01/1983
Copyright © 1983 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 JCOHome page
J. M. Collins
Imaging and Other Biomarkers in Early Clinical Studies: One Step at a Time or Re-Engineering Drug Development?
J. Clin. Oncol., August 20, 2005; 23(24): 5417 - 5419.
[Full Text] [PDF]

Home page
 JCOHome page
M. J. Ratain and S. G. Eckhardt
Phase II Studies of Modern Drugs Directed Against New Targets: If You Are Fazed, Too, Then Resist RECIST
J. Clin. Oncol., November 15, 2004; 22(22): 4442 - 4445.
[Full Text] [PDF]

Home page
 JCOHome page
G. Hudes, N. Haas, G. Yeslow, T. Gillon, P. O. Gunnarsson, M. Ellman, O. Nordle, B. Eriksson, L. Miller, L. Cisar, et al.
Phase I Clinical and Pharmacologic Trial of Intravenous Estramustine Phosphate
J. Clin. Oncol., February 15, 2002; 20(4): 1115 - 1127.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1983 by the American Society for Pharmacology and Experimental Therapeutics